Moreover, this compound has shown promising toxicological characteristics, as we observed that treated mice were free of adverse effects, and showed a marked antitumor efficacy against different CRC preclinical models [50], including KRAS-mutated patient-derived xenografts (PDXs). The gene discussed is KRAS; the disease is colorectal carcinoma.